Drug Profile
Research programme: non-small cell lung cancer therapeutics - Benitec
Alternative Names: TribetarnaLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Childrens Cancer Institute Australia for Medical Research
- Developer Benitec Biopharma
- Class Small interfering RNA
- Mechanism of Action Beta III tubulin protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Australia (Parenteral)
- 11 Jan 2015 Research programme: non-small cell lung cancer therapeutics - Benitec is available for licensing as of 11 Jan 2015. http://www.benitec.com
- 08 Jan 2015 Pharmacodynamics data from a preclinical study in Pancreatic cell cancer released by Benitec Biopharma